{"id":"W4319460830","doi":"10.1093/bjd/ljac089","title":"Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials","year":2022,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; Queen's University","funders":"UCB Pharma; Manchester Biomedical Research Centre; National Institute for Health and Care Research","keywords":"Ustekinumab; Medicine; Secukinumab; Adalimumab; Psoriasis Area and Severity Index; Discontinuation; Adverse effect; Psoriasis; Dermatology; Dermatology Life Quality Index; Clinical trial; Internal medicine; Psoriatic arthritis; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003557815,0.0005762236,0.001807833,0.0002016345,0.0003295257,0.001248577,0.0005539284,0.00102543,0.002425957],"category_scores_gemma":[0.00258045,0.0002904991,0.002187247,0.0004255259,0.0005387192,0.0006034022,0.0002950218,0.002520279,0.0004754911],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005231308,"about_ca_system_score_gemma":0.0006908015,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003984109,"about_ca_topic_score_gemma":0.0009366548,"domain_scores_codex":[0.9989948,0.0005232436,0.00009714413,0.0001328692,0.0001428358,0.0001091955],"domain_scores_gemma":[0.9982983,0.0005536974,0.0005039749,0.0001216577,0.0001371258,0.000385203],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6811826,0.01071626,0.02545291,0.007370838,0.01086216,0.0001731415,0.0003062604,0.001342911,0.01023068,0.0004341335,0.01091861,0.2410096],"study_design_scores_gemma":[0.7328706,0.1498328,0.08957113,0.001327041,0.006538816,0.0008833174,0.0001704189,0.001466392,0.002894998,0.0009413731,0.01342599,0.00007696269],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9261376,0.06310607,0.000449369,0.001566925,0.0003460421,0.001090788,0.001525857,0.0001015293,0.005675836],"genre_scores_gemma":[0.9773126,0.01466208,0.0008742122,0.002312266,0.0003597748,0.001033868,0.002289494,0.00002562855,0.001130154],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003557815,"threshold_uncertainty_score":0.01881576,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01907863473431349,"score_gpt":0.2518359652470177,"score_spread":0.2327573305127043,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}